However, studies on genetic and epigenetic aberrations in VIN and VSCC are limited.1, 2, 12, 13, 14, 15, 16TP53 mutations are frequently (~30%) detected in HPV‐negative VSCC as well as HPV‐negative VIN (~21%), suggesting that TP53 mutations might be involved at an early stage.1 Immunohistochemically HPV‐positive VIN shows usually absence of p53 and strong p16 expression.2 VSCC exhibit frequent gains of chromosome 3q and 8q, and losses of 3p, 8p, and 11q.12, 14, 16, 17, 18, 19, 20, 21. This evidence concerns the gene TP53 and vulvar intraepithelial neoplasia.